Welcome to our dedicated page for Centessa Pharmaceuticals Plc SEC filings (Ticker: CNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Centessa Pharmaceuticals plc filings document the regulatory record of a clinical-stage pharmaceutical issuer with American Depositary Shares listed on Nasdaq, each representing one ordinary share. Disclosures cover its orexin receptor 2 (OX2R) agonist focus, operating and financial results, corporate presentations, risk and capital-structure matters, and securities registered in connection with the ADS program.
Centessa's SEC filings also include Form 8-K material-event reports for underwriting and at-the-market sales agreements, public offerings of ADSs, executive and board changes, employment and advisory arrangements, and Regulation FD materials. Proxy filings describe governance, shareholder voting matters, compensation topics, and related public-company controls.
Centessa Pharmaceuticals plc (CNTA) reported interim results through June 30, 2025 showing continued clinical progress and a material licensing transaction. For the six months ended June 30, 2025 the company recorded a net loss of $76.5 million versus $81.9 million in the prior year period, with research and development expense of $76.2 million driven primarily by the OX2R agonist programs. Centessa recognized a $15.0 million upfront payment from a LockBody license to Genmab and constrained additional milestone consideration pending achievement. As of June 30, 2025 the company held $404.1 million of cash, cash equivalents and investments and expects those resources to fund operations into mid-2027. The balance sheet shows $109.5 million of long-term debt and an accumulated deficit of $1.07 billion. Operational updates include ORX750 in an ongoing Phase 2a study, IND clearance and Phase 1 initiation for ORX142, and the prior-phase discontinuation of SerpinPC with related termination charges largely paid down.
Centessa Pharmaceuticals plc furnished an earnings update by filing a current report. On August 12, 2025, the company announced its financial results for the quarter ended June 30, 2025 and provided the details in a press release attached as Exhibit 99.1. The report clarifies that this press release is being furnished, not filed, which limits how it is treated under U.S. securities laws.